Dr. Wencke Waltervom 03.12.2019Analysis of pharmacogenomic variants by WGS data for AML patients with altered response to treatment
Estimated reading time: 4 minutes
With the decrease of sequencing costs, the number of freely available "omics" data sets also increases, opening a nearly unlimited quantity of molecular genetic information. For the last decades the classical way of elucidating multifaceted molecular networks of diseases has been to break down the system into smaller, more traceable parts.
Dr. Wencke Waltervom 02.12.2019AML and MDS – the ever-expanding potential of genetics to define clinically relevant subclasses
Estimated reading time: 6 minutes
For nearly half a century acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) have been separated according to the percentage of bone marrow blasts. However, the last ten years have shown that the incorporation of genetic information in the classification improves its accuracy in diagnosis and prognosis.
Dr. Wencke Waltervom 18.11.2019Large-scale sequencing experience from the MLL 5K project
Estimated reading time: 5 minutes
The project was started in 2017 with the aim to sequence the genome and transcriptome of 5,000 patients with haematological malignancies, in order to obtain a more in-depth knowledge of their molecular profiles to better understand the underlying complexity, to refine diagnosis, and also to take another step in the direction of personalized medicine.